Flexible and Robust Methods for Rare‐Variant Testing of Quantitative Traits in Trios and Nuclear Families

Most rare‐variant association tests for complex traits are applicable only to population‐based or case‐control resequencing studies. There are fewer rare‐variant association tests for family‐based resequencing studies, which is unfortunate because pedigrees possess many attractive characteristics for such analyses. Family‐based studies can be more powerful than their population‐based counterparts due to increased genetic load and further enable the implementation of rare‐variant association tests that, by design, are robust to confounding due to population stratification. With this in mind, we propose a rare‐variant association test for quantitative traits in families; this test integrates the QTDT approach of Abecasis et al. [Abecasis et al., 2000a ] into the kernel‐based SNP association test KMFAM of Schifano et al. [Schifano et al., 2012 ]. The resulting within‐family test enjoys the many benefits of the kernel framework for rare‐variant association testing, including rapid evaluation of P‐values and preservation of power when a region harbors rare causal variation that acts in different directions on phenotype. Additionally, by design, this within‐family test is robust to confounding due to population stratification. Although within‐family association tests are generally less powerful than their counterparts that use all genetic information, we show that we can recover much of this power (although still ensuring robustness to population stratification) using a straightforward screening procedure. Our method accommodates covariates and allows for missing parental genotype data, and we have written software implementing the approach in R for public use.     

Power of Family‐Based Association Designs to Detect Rare Variants in Large Pedigrees Using Imputed Genotypes

Recently, the “Common Disease‐Multiple Rare Variants” hypothesis has received much attention, especially with current availability of next‐generation sequencing. Family‐based designs are well suited for discovery of rare variants, with large and carefully selected pedigrees enriching for multiple copies of such variants. However, sequencing a large number of samples is still prohibitive. Here, we evaluate a cost‐effective strategy (pseudosequencing) to detect association with rare variants in large pedigrees. This strategy consists of sequencing a small subset of subjects, genotyping the remaining sampled subjects on a set of sparse markers, and imputing the untyped markers in the remaining subjects conditional on the sequenced subjects and pedigree information. We used a recent pedigree imputation method (GIGI), which is able to efficiently handle large pedigrees and accurately impute rare variants. We used burden and kernel association tests, famWS and famSKAT, which both account for family relationships and heterogeneity of allelic effect for famSKAT only. We simulated pedigree sequence data and compared the power of association tests for pseudosequence data, a subset of sequence data used for imputation, and all subjects sequenced. We also compared, within the pseudosequence data, the power of association test using best‐guess genotypes and allelic dosages. Our results show that the pseudosequencing strategy considerably improves the power to detect association with rare variants. They also show that the use of allelic dosages results in much higher power than use of best‐guess genotypes in these family‐based data. Moreover, famSKAT shows greater power than famWS in most of scenarios we considered.     

Region‐based association tests for sequencing data on survival traits

Family‐based designs enriched with affected subjects and disease associated variants can increase statistical power for identifying functional rare variants. However, few rare variant analysis approaches are available for time‐to‐event traits in family designs and none of them applicable to the X chromosome. We developed novel pedigree‐based burden and kernel association tests for time‐to‐event outcomes with right censoring for pedigree data, referred to FamRATS (family‐based rare variant association tests for survival traits). Cox proportional hazard models were employed to relate a time‐to‐event trait with rare variants with flexibility to encompass all ranges and collapsing of multiple variants. In addition, the robustness of violating proportional hazard assumptions was investigated for the proposed and four current existing tests, including the conventional population‐based Cox proportional model and the burden, kernel, and sum of squares statistic (SSQ) tests for family data. The proposed tests can be applied to large‐scale whole‐genome sequencing data. They are appropriate for the practical use under a wide range of misspecified Cox models, as well as for population‐based, pedigree‐based, or hybrid designs. In our extensive simulation study and data example, we showed that the proposed kernel test is the most powerful and robust choice among the proposed burden test and the existing four rare variant survival association tests. When applied to the Diabetes Heart Study, the proposed tests found exome variants of the JAK1 gene on chromosome 1 showed the most significant association with age at onset of type 2 diabetes from the exome‐wide analysis.     

Adjusting Family Relatedness in Data‐driven Burden Test of Rare Variants

Family data represent a rich resource for detecting association between rare variants (RVs) and human traits. However, most RV association analysis methods developed in recent years are data‐driven burden tests which can adaptively learn weights from data but require permutation to evaluate significance, thus are not readily applicable to family data, because random permutation will destroy family structure. Direct application of these methods to family data may result in a significant inflation of false positives. To overcome this issue, we have developed a generalized, weighted sum mixed model (WSMM), and corresponding computational techniques that can incorporate family information into data‐driven burden tests, and allow adaptive and efficient permutation test in family data. Using simulated and real datasets, we demonstrate that the WSMM method can be used to appropriately adjust for genetic relatedness among family members and has a good control for the inflation of false positives. We compare WSMM with a nondata‐driven, family‐based Sequence Kernel Association Test (famSKAT), showing that WSMM has significantly higher power in some cases. WSMM provides a generalized, flexible framework for adapting different data‐driven burden tests to analyze data with any family structures, and it can be extended to binary and time‐to‐onset traits, with or without covariates.     

Leveraging population information in family‐based rare variant association analyses of quantitative traits

Confounding due to population substructure is always a concern in genetic association studies. Although methods have been proposed to adjust for population stratification in the context of common variation, it is unclear how well these approaches will work when interrogating rare variation. Family‐based association tests can be constructed that are robust to population stratification. For example, when considering a quantitative trait, a linear model can be used that decomposes genetic effects into between‐ and within‐family components and a test of the within‐family component is robust to population stratification. However, this within‐family test ignores between‐family information potentially leading to a loss of power. Here, we propose a family‐based two‐stage rare‐variant test for quantitative traits. We first construct a weight for each variant within a gene, or other genetic unit, based on score tests of between‐family effect parameters. These weights are then used to combine variants using score tests of within‐family effect parameters. Because the between‐family and within‐family tests are orthogonal under the null hypothesis, this two‐stage approach can increase power while still maintaining validity. Using simulation, we show that this two‐stage test can significantly improve power while correctly maintaining type I error. We further show that the two‐stage approach maintains the robustness to population stratification of the within‐family test and we illustrate this using simulations reflecting samples composed of continental and closely related subpopulations.     

Gene‐based segregation method for identifying rare variants in family‐based sequencing studies

Whole‐exome sequencing using family data has identified rare coding variants in Mendelian diseases or complex diseases with Mendelian subtypes, using filters based on variant novelty, functionality, and segregation with the phenotype within families. However, formal statistical approaches are limited. We propose a gene‐based segregation test (GESE) that quantifies the uncertainty of the filtering approach. It is constructed using the probability of segregation events under the null hypothesis of Mendelian transmission. This test takes into account different degrees of relatedness in families, the number of functional rare variants in the gene, and their minor allele frequencies in the corresponding population. In addition, a weighted version of this test allows incorporating additional subject phenotypes to improve statistical power. We show via simulations that the GESE and weighted GESE tests maintain appropriate type I error rate, and have greater power than several commonly used region‐based methods. We apply our method to whole‐exome sequencing data from 49 extended pedigrees with severe, early‐onset chronic obstructive pulmonary disease (COPD) in the Boston Early‐Onset COPD study (BEOCOPD) and identify several promising candidate genes. Our proposed methods show great potential for identifying rare coding variants of large effect and high penetrance for family‐based sequencing data. The proposed tests are implemented in an R package that is available on CRAN ( https://cran.r-project.org/web/packages/GESE/ ).     

A Novel Test for Testing the Optimally Weighted Combination of Rare and Common Variants Based on Data of Parents and Affected Children

With the development of sequencing technologies, the direct testing of rare variant associations has become possible. Many statistical methods for detecting associations between rare variants and complex diseases have recently been developed, most of which are population‐based methods for unrelated individuals. A limitation of population‐based methods is that spurious associations can occur when there is a population structure. For rare variants, this problem can be more serious, because the spectrum of rare variation can be very different in diverse populations, as well as the current nonexistence of methods to control for population stratification in population‐based rare variant associations. A solution to the problem of population stratification is to use family‐based association tests, which use family members to control for population stratification. In this article, we propose a novel test for Testing the Optimally Weighted combination of variants based on data of Parents and Affected Children (TOW‐PAC). TOW‐PAC is a family‐based association test that tests the combined effect of rare and common variants in a genomic region, and is robust to the directions of the effects of causal variants. Simulation studies confirm that, for rare variant associations, family‐based association tests are robust to population stratification although population‐based association tests can be seriously confounded by population stratification. The results of power comparisons show that the power of TOW‐PAC increases with an increase of the number of affected children in each family and TOW‐PAC based on multiple affected children per family is more powerful than TOW based on unrelated individuals.     

Sequence Kernel Association Test for Quantitative Traits in Family Samples

A large number of rare genetic variants have been discovered with the development in sequencing technology and the lowering of sequencing costs. Rare variant analysis may help identify novel genes associated with diseases and quantitative traits, adding to our knowledge of explaining heritability of these phenotypes. Many statistical methods for rare variant analysis have been developed in recent years, but some of them require the strong assumption that all rare variants in the analysis share the same direction of effect, and others requiring permutation to calculate the P‐values are computer intensive. Among these methods, the sequence kernel association test (SKAT) is a powerful method under many different scenarios. It does not require any assumption on the directionality of effects, and statistical significance is computed analytically. In this paper, we extend SKAT to be applicable to family data. The family‐based SKAT (famSKAT) has a different test statistic and null distribution compared to SKAT, but is equivalent to SKAT when there is no familial correlation. Our simulation studies show that SKAT has inflated type I error if familial correlation is inappropriately ignored, but has appropriate type I error if applied to a single individual per family to obtain an unrelated subset. In contrast, famSKAT has the correct type I error when analyzing correlated observations, and it has higher power than competing methods in many different scenarios. We illustrate our approach to analyze the association of rare genetic variants using glycemic traits from the Framingham Heart Study.     

A Fast and Noise‐Resilient Approach to Detect Rare‐Variant Associations With Deep Sequencing Data for Complex Disorders

Next generation sequencing technology has enabled the paradigm shift in genetic association studies from the common disease/common variant to common disease/rare‐variant hypothesis. Analyzing individual rare variants is known to be underpowered; therefore association methods have been developed that aggregate variants across a genetic region, which for exome sequencing is usually a gene. The foreseeable widespread use of whole genome sequencing poses new challenges in statistical analysis. It calls for new rare‐variant association methods that are statistically powerful, robust against high levels of noise due to inclusion of noncausal variants, and yet computationally efficient. We propose a simple and powerful statistic that combines the disease‐associated P‐values of individual variants using a weight that is the inverse of the expected standard deviation of the allele frequencies under the null. This approach, dubbed as Sigma‐P method, is extremely robust to the inclusion of a high proportion of noncausal variants and is also powerful when both detrimental and protective variants are present within a genetic region. The performance of the Sigma‐P method was tested using simulated data based on realistic population demographic and disease models and its power was compared to several previously published methods. The results demonstrate that this method generally outperforms other rare‐variant association methods over a wide range of models. Additionally, sequence data on the ANGPTL family of genes from the Dallas Heart Study were tested for associations with nine metabolic traits and both known and novel putative associations were uncovered using the Sigma‐P method.     

Methods for Association Analysis and Meta‐Analysis of Rare Variants in Families

Advances in exome sequencing and the development of exome genotyping arrays are enabling explorations of association between rare coding variants and complex traits. To ensure power for these rare variant analyses, a variety of association tests that group variants by gene or functional unit have been proposed. Here, we extend these tests to family‐based studies. We develop family‐based burden tests, variable frequency threshold tests and sequence kernel association tests. Through simulations, we compare the performance of different tests. We describe situations where family‐based studies provide greater power than studies of unrelated individuals to detect rare variants associated with moderate to large changes in trait values. Broadly speaking, we find that when sample sizes are limited and only a modest fraction of all trait‐associated variants can be identified, family samples are more powerful. Finally, we illustrate our approach by analyzing the relationship between coding variants and levels of high‐density lipoprotein (HDL) cholesterol in 11,556 individuals from the HUNT and SardiNIA studies, demonstrating association for coding variants in the APOC3, CETP, LIPC, LIPG, and LPL genes and illustrating the value of family samples, meta‐analysis, and gene‐level tests. Our methods are implemented in freely available C++ code.     

Genome‐Wide Association Analysis of Imputed Rare Variants: Application to Seven Common Complex Diseases

Genome‐wide association studies have been successful in identifying loci contributing effects to a range of complex human traits. The majority of reproducible associations within these loci are with common variants, each of modest effect, which together explain only a small proportion of heritability. It has been suggested that much of the unexplained genetic component of complex traits can thus be attributed to rare variation. However, genome‐wide association study genotyping chips have been designed primarily to capture common variation, and thus are underpowered to detect the effects of rare variants. Nevertheless, we demonstrate here, by simulation, that imputation from an existing scaffold of genome‐wide genotype data up to high‐density reference panels has the potential to identify rare variant associations with complex traits, without the need for costly re‐sequencing experiments. By application of this approach to genome‐wide association studies of seven common complex diseases, imputed up to publicly available reference panels, we identify genome‐wide significant evidence of rare variant association in PRDM10 with coronary artery disease and multiple genes in the major histocompatibility complex (MHC) with type 1 diabetes. The results of our analyses highlight that genome‐wide association studies have the potential to offer an exciting opportunity for gene discovery through association with rare variants, conceivably leading to substantial advancements in our understanding of the genetic architecture underlying complex human traits.     

A General Efficient and Flexible Approach for Genome‐Wide Association Analyses of Imputed Genotypes in Family‐Based Designs

Genotype imputation is a critical technique for following up genome‐wide association studies. Efficient methods are available for dealing with the probabilistic nature of imputed single nucleotide polymorphisms (SNPs) in population‐based designs, but not for family‐based studies. We have developed a new analytical approach (FBATdosage), using imputed allele dosage in the general framework of family‐based association tests to bridge this gap. Simulation studies showed that FBATdosage yielded highly consistent type I error rates, whatever the level of genotype uncertainty, and a much higher power than the best‐guess genotype approach. FBATdosage allows fast linkage and association testing of several million of imputed variants with binary or quantitative phenotypes in nuclear families of arbitrary size with arbitrary missing data for the parents. The application of this approach to a family‐based association study of leprosy susceptibility successfully refined the association signal at two candidate loci, C1orf141‐IL23R on chromosome 1 and RAB32‐C6orf103 on chromosome 6.     

GEE‐Based SNP Set Association Test for Continuous and Discrete Traits in Family‐Based Association Studies

Family‐based genetic association studies of related individuals provide opportunities to detect genetic variants that complement studies of unrelated individuals. Most statistical methods for family association studies for common variants are single marker based, which test one SNP a time. In this paper, we consider testing the effect of an SNP set, e.g., SNPs in a gene, in family studies, for both continuous and discrete traits. Specifically, we propose a generalized estimating equations (GEEs) based kernel association test, a variance component based testing method, to test for the association between a phenotype and multiple variants in an SNP set jointly using family samples. The proposed approach allows for both continuous and discrete traits, where the correlation among family members is taken into account through the use of an empirical covariance estimator. We derive the theoretical distribution of the proposed statistic under the null and develop analytical methods to calculate the P‐values. We also propose an efficient resampling method for correcting for small sample size bias in family studies. The proposed method allows for easily incorporating covariates and SNP‐SNP interactions. Simulation studies show that the proposed method properly controls for type I error rates under both random and ascertained sampling schemes in family studies. We demonstrate through simulation studies that our approach has superior performance for association mapping compared to the single marker based minimum P‐value GEE test for an SNP‐set effect over a range of scenarios. We illustrate the application of the proposed method using data from the Cleveland Family GWAS Study.     

Testing Genetic Association With Rare Variants in Admixed Populations

Recent studies suggest that rare variants play an important role in the etiology of many traits. Although a number of methods have been developed for genetic association analysis of rare variants, they all assume a relatively homogeneous population under study. Such an assumption may not be valid for samples collected from admixed populations such asAfricanAmericans andHispanicAmericans as there is a great extent of local variation in ancestry in these populations. To ensure valid and more powerful rare variant association tests performed in admixed populations, we have developed a local ancestry‐based weighted dosage test, which is able to take into account local ancestry of rare alleles, uncertainties in rare variant imputation when imputed data are included, and the direction of effect that rare variants exert on phenotypic outcome. We used simulated sequence data to show that our proposed test has controlled typeIerror rates, whereas naïve application of existing rare variants tests and tests that adjust for global ancestry lead to inflated type I error rates. We showed that our test has higher power than tests without proper adjustment of ancestry. We also applied the proposed method to a candidate gene study on low‐density lipoprotein cholesterol. Our results suggest that it is important to appropriately control for potential population stratification induced by local ancestry difference in the analysis of rare variants in admixed populations.     

Generalized Functional Linear Models for Gene‐Based Case‐Control Association Studies

By using functional data analysis techniques, we developed generalized functional linear models for testing association between a dichotomous trait and multiple genetic variants in a genetic region while adjusting for covariates. Both fixed and mixed effect models are developed and compared. Extensive simulations show that Rao's efficient score tests of the fixed effect models are very conservative since they generate lower type I errors than nominal levels, and global tests of the mixed effect models generate accurate type I errors. Furthermore, we found that the Rao's efficient score test statistics of the fixed effect models have higher power than the sequence kernel association test (SKAT) and its optimal unified version (SKAT‐O) in most cases when the causal variants are both rare and common. When the causal variants are all rare (i.e., minor allele frequencies less than 0.03), the Rao's efficient score test statistics and the global tests have similar or slightly lower power than SKAT and SKAT‐O. In practice, it is not known whether rare variants or common variants in a gene region are disease related. All we can assume is that a combination of rare and common variants influences disease susceptibility. Thus, the improved performance of our models when the causal variants are both rare and common shows that the proposed models can be very useful in dissecting complex traits. We compare the performance of our methods with SKAT and SKAT‐O on real neural tube defects and Hirschsprung's disease datasets. The Rao's efficient score test statistics and the global tests are more sensitive than SKAT and SKAT‐O in the real data analysis. Our methods can be used in either gene‐disease genome‐wide/exome‐wide association studies or candidate gene analyses.     

MF‐TOWmuT: Testing an optimally weighted combination of common and rare variants with multiple traits using family data

With rapid advancements of sequencing technologies and accumulations of electronic health records, a large number of genetic variants and multiple correlated human complex traits have become available in many genetic association studies. Thus, it becomes necessary and important to develop new methods that can jointly analyze the association between multiple genetic variants and multiple traits. Compared with methods that only use a single marker or trait, the joint analysis of multiple genetic variants and multiple traits is more powerful since such an analysis can fully incorporate the correlation structure of genetic variants and/or traits and their mutual dependence patterns. However, most of existing methods that simultaneously analyze multiple genetic variants and multiple traits are only applicable to unrelated samples. We develop a new method called MF‐TOWmuT to detect association of multiple phenotypes and multiple genetic variants in a genomic region with family samples. MF‐TOWmuT is based on an optimally weighted combination of variants. Our method can be applied to both rare and common variants and both qualitative and quantitative traits. Our simulation results show that (1) the type I error of MF‐TOWmuT is preserved; (2) MF‐TOWmuT outperforms two existing methods such as Multiple Family‐based Quasi‐Likelihood Score Test and Multivariate Family‐based Rare Variant Association Test in terms of power. We also illustrate the usefulness of MF‐TOWmuT by analyzing genotypic and phenotipic data from the Genetics of Kidneys in Diabetes study. R program is available at https://github.com/gaochengPRC/MF-TOWmuT .     

Population genetic simulation study of power in association testing across genetic architectures and study designs

While it is well established that genetics can be a major contributor to population variation of complex traits, the relative contributions of rare and common variants to phenotypic variation remains a matter of considerable debate. Here, we simulate genetic and phenotypic data across different case/control panel sampling strategies, sequencing methods, and genetic architecture models based on evolutionary forces to determine the statistical performance of rare variant association tests (RVATs) widely in use. We find that the highest statistical power of RVATs is achieved by sampling case/control individuals from the extremes of an underlying quantitative trait distribution. We also demonstrate that the use of genotyping arrays, in conjunction with imputation from a whole-genome sequenced (WGS) reference panel, recovers the vast majority (90%) of the power that could be achieved by sequencing the case/control panel using current tools. Finally, we show that for dichotomous traits, the statistical performance of RVATs decreases as rare variants become more important in the trait architecture. Our results extend previous work to show that RVATs are insufficiently powered to make generalizable conclusions about the role of rare variants in dichotomous complex traits.     

Powerful and robust cross‐phenotype association test for case‐parent trios

There has been increasing interest in identifying genes within the human genome that influence multiple diverse phenotypes. In the presence of pleiotropy, joint testing of these phenotypes is not only biologically meaningful but also statistically more powerful than univariate analysis of each separate phenotype accounting for multiple testing. Although many cross‐phenotype association tests exist, the majority of such methods assume samples composed of unrelated subjects and therefore are not applicable to family‐based designs, including the valuable case‐parent trio design. In this paper, we describe a robust gene‐based association test of multiple phenotypes collected in a case‐parent trio study. Our method is based on the kernel distance covariance (KDC) method, where we first construct a similarity matrix for multiple phenotypes and a similarity matrix for genetic variants in a gene; we then test the dependency between the two similarity matrices. The method is applicable to either common variants or rare variants in a gene, and resulting tests from the method are by design robust to confounding due to population stratification. We evaluated our method through simulation studies and observed that the method is substantially more powerful than standard univariate testing of each separate phenotype. We also applied our method to phenotypic and genotypic data collected in case‐parent trios as part of the Genetics of Kidneys in Diabetes (GoKinD) study and identified a genome‐wide significant gene demonstrating cross‐phenotype effects that was not identified using standard univariate approaches.     

Pathway‐Based Approaches for Sequencing‐Based Genome‐Wide Association Studies

For analyzing complex trait association with sequencing data, most current studies test aggregated effects of variants in a gene or genomic region. Although gene‐based tests have insufficient power even for moderately sized samples, pathway‐based analyses combine information across multiple genes in biological pathways and may offer additional insight. However, most existing pathway association methods are originally designed for genome‐wide association studies, and are not comprehensively evaluated for sequencing data. Moreover, region‐based rare variant association methods, although potentially applicable to pathway‐based analysis by extending their region definition to gene sets, have never been rigorously tested. In the context of exome‐based studies, we use simulated and real datasets to evaluate pathway‐based association tests. Our simulation strategy adopts a genome‐wide genetic model that distributes total genetic effects hierarchically into pathways, genes, and individual variants, allowing the evaluation of pathway‐based methods with realistic quantifiable assumptions on the underlying genetic architectures. The results show that, although no single pathway‐based association method offers superior performance in all simulated scenarios, a modification of Gene Set Enrichment Analysis approach using statistics from single‐marker tests without gene‐level collapsing (weighted Kolmogrov‐Smirnov [WKS]‐Variant method) is consistently powerful. Interestingly, directly applying rare variant association tests (e.g., sequence kernel association test) to pathway analysis offers a similar power, but its results are sensitive to assumptions of genetic architecture. We applied pathway association analysis to an exome‐sequencing data of the chronic obstructive pulmonary disease, and found that the WKS‐Variant method confirms associated genes previously published.     

Rare‐variant association tests in longitudinal studies,with an application to the Multi‐Ethnic Study of Atherosclerosis (MESA)

Over the past few years, an increasing number of studies have identified rare variants that contribute to trait heritability. Due to the extreme rarity of some individual variants, gene‐based association tests have been proposed to aggregate the genetic variants within a gene, pathway, or specific genomic region as opposed to a one‐at‐a‐time single variant analysis. In addition, in longitudinal studies, statistical power to detect disease susceptibility rare variants can be improved through jointly testing repeatedly measured outcomes, which better describes the temporal development of the trait of interest. However, usual sandwich/model‐based inference for sequencing studies with longitudinal outcomes and rare variants can produce deflated/inflated type I error rate without further corrections. In this paper, we develop a group of tests for rare‐variant association based on outcomes with repeated measures. We propose new perturbation methods such that the type I error rate of the new tests is not only robust to misspecification of within‐subject correlation, but also significantly improved for variants with extreme rarity in a study with small or moderate sample size. Through extensive simulation studies, we illustrate that substantially higher power can be achieved by utilizing longitudinal outcomes and our proposed finite sample adjustment. We illustrate our methods using data from the Multi‐Ethnic Study of Atherosclerosis for exploring association of repeated measures of blood pressure with rare and common variants based on exome sequencing data on 6,361 individuals.